In a dual-center study comprising 7,246 COVID-19 patients, including 12 with Down syndrome, levels of inflammation markers, such as C-reactive protein and IL-6, were not much different between 12 patients with Down syndrome and 60 patients without, but the Down syndrome patients had more severe disease (29). The gene discussed is IL6; the disease is Down syndrome.